Company Transgene

Equities

TNG

FR0005175080

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:08:01 2024-03-28 pm EDT 5-day change 1st Jan Change
1.14 EUR +2.52% Intraday chart for Transgene -1.72% -16.79%

Business Summary

Transgene, part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on discovering and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells.

Transgene has a portfolio of 5 products in clinical development: TG4050, the first individualized therapeutic vaccine based on the myvac® platform, TG4001 a therapeutic vaccine for HPV positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO® viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology.

Transgene is based in Strasbourg, France, and has additional operations in Lyon and China.

Number of employees: 143

Sales per Business

EUR in Million2021Weight2022Weight Delta
Research and Development Collaboration
100.0 %
3 29.3 % 3 100.0 % +6.73%

Sales per region

EUR in Million2021Weight2022Weight Delta
France
100.0 %
10 100.0 % 3 100.0 % -68.72%

Managers

Managers TitleAgeSince
Chief Executive Officer 63 22-03-30
Director of Finance/CFO - 16-03-31
Chief Tech/Sci/R&D Officer 70 16-03-16
Chief Tech/Sci/R&D Officer 60 14-08-31
Director/Board Member 43 19-04-30
Director/Board Member 63 04-12-06
Corporate Officer/Principal 60 -
Human Resources Officer 40 21-01-13
General Counsel 54 16-03-16

Members of the board

Members of the board TitleAgeSince
Director/Board Member 74 13-06-18
Director/Board Member 63 04-12-06
Director/Board Member 59 99-12-31
Chief Executive Officer 63 22-03-30
Director/Board Member 71 16-12-31
Director/Board Member 47 16-12-31
Director/Board Member 61 22-05-24
Director/Board Member 68 23-05-04
Director/Board Member 43 19-04-30
Director/Board Member - 20-12-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 100,850,273 35,018,669 ( 34.72 %) 0 34.72 %

Shareholders

NameEquities%Valuation
Compagnie Merieux Alliance SAS
60.02 %
60,527,665 60.02 % 68 M €
4,824,856 4.784 % 5 M €
BFT Investment Managers SA
0.8854 %
892,917 0.8854 % 1 M €
TRANSGENE
0.2840 %
286,436 0.2840 % 322 367 €
Tocqueville Finance SA
0.2420 %
244,101 0.2420 % 274 721 €
Erasmus Gestion SAS
0.1733 %
174,744 0.1733 % 196 664 €
Financière Arbevel SA
0.0863 %
87,000 0.0863 % 97 913 €
74,403 0.0738 % 83 736 €
La Mondiale SAM (Investment Portfolio)
0.0669 %
67,422 0.0669 % 75 879 €
Neuflize Vie SA
0.0638 %
64,387 0.0638 % 72 464 €

Holdings

NameEquities%Valuation
286,436 0.28% 322,367 $

Company contact information

Transgene SA

400, boulevard Gonthier d'Andernach Parc d'Innovation

67405, Strasbourg

+33 3 88 27 91 00

http://www.transgene.fr
address Transgene(TNG)

Sales per Business

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.14 EUR
Average target price
3.5 EUR
Spread / Average Target
+207.02%
Consensus

Annual profits - Rate of surprise